ArTS Archivio della ricerca di Trieste

GENERALI, DANIELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 17.909
EU - Europa 9.063
AS - Asia 3.272
AF - Africa 39
SA - Sud America 39
OC - Oceania 22
Continente sconosciuto - Info sul continente non disponibili 4
Totale 30.348
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 17.866
PL - Polonia 4.590
IT - Italia 1.289
SE - Svezia 1.123
SG - Singapore 1.023
CN - Cina 925
HK - Hong Kong 664
UA - Ucraina 442
DE - Germania 393
TR - Turchia 321
BG - Bulgaria 257
IE - Irlanda 256
FI - Finlandia 249
VN - Vietnam 117
GB - Regno Unito 92
RU - Federazione Russa 75
ES - Italia 57
IN - India 54
FR - Francia 49
BE - Belgio 47
MY - Malesia 37
BR - Brasile 27
CA - Canada 27
NL - Olanda 27
JP - Giappone 25
RO - Romania 24
AU - Australia 20
IL - Israele 19
KR - Corea 19
CH - Svizzera 16
AT - Austria 14
MX - Messico 12
SN - Senegal 12
TH - Thailandia 11
TW - Taiwan 11
EE - Estonia 10
IR - Iran 10
CZ - Repubblica Ceca 9
DK - Danimarca 8
EG - Egitto 7
CL - Cile 6
HU - Ungheria 6
PK - Pakistan 6
SA - Arabia Saudita 6
ZA - Sudafrica 6
GR - Grecia 5
JO - Giordania 5
MD - Moldavia 5
RS - Serbia 5
A2 - ???statistics.table.value.countryCode.A2??? 4
AM - Armenia 4
DZ - Algeria 4
HR - Croazia 4
SC - Seychelles 4
AZ - Azerbaigian 3
CI - Costa d'Avorio 3
PT - Portogallo 3
AR - Argentina 2
BO - Bolivia 2
CR - Costa Rica 2
DO - Repubblica Dominicana 2
LT - Lituania 2
NZ - Nuova Zelanda 2
OM - Oman 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
SY - Repubblica araba siriana 2
TN - Tunisia 2
AE - Emirati Arabi Uniti 1
BN - Brunei Darussalam 1
EC - Ecuador 1
GE - Georgia 1
ID - Indonesia 1
IQ - Iraq 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
LV - Lettonia 1
MA - Marocco 1
NP - Nepal 1
PE - Perù 1
PH - Filippine 1
Totale 30.348
Salva come PNG Salva come JPEG
Città #
Warsaw 4.575
Fairfield 2.614
Woodbridge 1.992
Houston 1.620
Ashburn 1.370
Ann Arbor 1.351
Chandler 1.115
Wilmington 1.101
Seattle 1.076
Cambridge 955
Singapore 884
Hong Kong 651
Jacksonville 601
Princeton 472
Boardman 448
Trieste 436
Santa Clara 310
Izmir 308
Columbus 300
Dublin 256
Sofia 256
Beijing 239
San Diego 128
Dong Ket 108
Dearborn 68
Helsinki 67
Falls Church 64
Milan 61
Bremen 51
Brussels 39
Redwood City 39
Norwalk 38
Dongguan 37
Phoenix 35
Kerken 34
Chicago 30
Duino-Aurisina 30
Rome 29
Dallas 26
Redmond 26
New York 25
Nanjing 24
Shanghai 24
Hefei 23
Lappeenranta 23
Venice 22
Buffalo 21
Des Moines 21
Fremont 21
London 21
Guangzhou 20
Jinan 20
Los Angeles 20
São Paulo 19
Barcelona 18
Udine 18
Amsterdam 17
Munich 17
Padova 17
Pignone 17
Tel Aviv 17
Kunming 16
Madrid 16
San Antonio 16
Toronto 16
Tappahannock 15
Zhengzhou 15
Florence 14
Hangzhou 14
Tokyo 14
Dottingen 13
Turin 13
Boydton 12
Dakar 12
Horia 12
Paris 12
Seoul 12
Shenyang 12
Montegaldella 11
Vienna 11
Edinburgh 10
Nanchang 10
San Francisco 10
Bangkok 9
Fuzhou 9
Schoenwalde 9
Tianjin 9
Toenisvorst 9
Indiana 8
Mumbai 8
Pune 8
Turku 8
Moscow 7
Venezia 7
Bologna 6
Brescia 6
Changsha 6
Council Bluffs 6
Frankfurt am Main 6
Freiburg im Breisgau 6
Totale 24.678
Salva come PNG Salva come JPEG
Nome #
Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration 375
Cyclin dependent kinase 4 and 6 inhibitors as novel therapeutic agents for targeted treatment of malignant mesothelioma 374
Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer 351
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial 329
Efficacy and safety of T-DM1 in the 'common-practice' of HER2+ advanced breast cancer setting: a multicenter study 324
Advances in systemic therapy for metastatic breast cancer: future perspectives 323
Current challenges in HER2-positive breast cancer 317
PIK3CA mutation in gastric cancer and the role of microsatellite instability status in mutations of exons 9 and 20 of the PIK3CA gene 317
Cell-free DNA integrity for the monitoring of breast cancer: Future perspectives? 316
Enteric-coated and highly standardized cranberry extract reduces antibiotic and nonsteroidal anti-inflammatory drug use for urinary tract infections during radiotherapy for prostate carcinoma 314
Designing a broad-spectrum integrative approach for cancer prevention and treatment 309
Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition 304
Circulating tumor cells correlate with patterns of recurrence in patients with hormone-sensitive prostate cancer 295
Isolated testicular metastasis from prostate cancer 295
Characterization of MTAP gene expression in breast cancer patients and cell lines 293
NEODUCTGENESIS AS A PROGNOSTIC MARKER IN “DUCTAL” CARCINOMA IN SITU OF THE BREAST 288
Bevacizumab in small cell lung cancer 284
Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility 284
Would the combination of everolimus with endocrine-therapy help in FGFR2 positive serous endometrial cancer? 281
Broad targeting of angiogenesis for cancer prevention and therapy 275
Hypoxia-related biological markers as predictors of epirubicinbased treatment responsiveness and resistance in locally advanced breast cancer 275
Triple Negative Breast Cancers Have a Reduced Expression of DNA Repair Genes 273
Need for randomized clinical trials testing targeted therapies in malignant pleural mesothelioma 262
Current status of PI3K-mTOR inhibition in hormone-receptor positive, HER2-negative breast cancer 261
Association between ramucirumab-related hypertension and response to treatment in patients with metastatic gastric cancer 260
Platinum sensitivity and DNA repair in a recently established panel of patient-derived ovarian carcinoma xenografts 249
Targeting the androgenic pathway in elderly patients with castration-resistant prostate cancer: A meta-analysis of randomized trials 243
Tumour infiltrating lymphocytes and immune-related genes as predictors of outcome in pancreatic adenocarcinoma 243
Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit 240
The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells 239
PAK6-Associated Support Vector Machine Classifier: A New Way to Evaluate Response and Survival of Gastric Cancer Treated by 5-FU/Oxaliplatin Chemotherapy 238
Cell-free DNA analysis in healthy individuals by next-generation sequencing: a proof of concept and technical validation study. 231
Inhibitors of Tumor Angiogenesis 221
A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer 208
Abemaciclib: A CDK4/6 inhibitor for the treatment of HR+/HEeR2- advanced breast cancer 206
Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma 206
Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study 191
Correction: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study 178
Advances in systemic therapy for malignant mesothelioma: Future perspectives 176
Management of the axilla in breast cancer: outcome analysis in a series of ductal versus lobular invasive cancers 173
The prognostic value of PI3K mutational status in breast cancer: A meta-analysis 171
Low-Dose Oral Ethinylestradiol With Concomitant Low-Dose Acetylsalicylic Acid for Advanced Castrate-Resistant Prostate Cancer 170
PROGNOSTIC ROLE OF TUMOR INFILTRATING LYMPHOCITES (TILS) IN EPITHELIOID PLEURAL MESOTHELIOMA 170
COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment 167
The relevance of chemobrain in breast cancer survivors: An Italian exploratory study to measure incidence and psycho-social impact 167
The G-protein-coupled receptor CLR is upregulated in an autocrine loop with adrenomedullin in clear cell renal cell carcinoma and associated with poor prognosis 166
Benefit of the addition of hormone therapy to neoadjuvant anthracycline-based chemotherapy for breast cancer: comparison of predicted and observed pCR 164
CDK4/6 inhibitors in HER2-positive breast cancer 162
Apatinib for the treatment of gastric cancer 158
Low dose versus standard dose of corticosteroids in the management of adverse events of special interest from abiraterone acetate: data from a literature-based meta-analysis 158
Clinical validity of circulating tumour cells in patients with metastatic breast cancer: A pooled analysis of individual patient data 157
RNA disruption and drug response in breast cancer primary systemic therapy 151
Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer? 148
Different efficacy of ramucirumab in patients with metastatic gastric and gastroesophageal junction cancer according to ECOG performance status 147
Practice patterns regarding drains management in breast surgery: Results of a survey of Senonetwork Italia breast centers 146
Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer 145
International expert consensus on primary systemic therapy in the management of early breast cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013) 144
The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials 140
Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer 140
Predictive immunohistochemical biomarkers in the context of neoadjuvant therapy for breast cancer 139
Pertuzumab therapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer 139
Lenvatinib for the treatment of renal cell carcinoma 139
null 137
Neoadjuvant treatment approach: The rosetta stone for breast cancer? 136
Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancer 136
Ibrutinib: from bench side to clinical implications 135
High-dose chemotherapy with autologous hematopoietic stem cell transplantation for high-risk primary breast cancer 135
Prospective neoadjuvant analysis of PET imaging and mechanisms of resistance to Trastuzumab shows role of HIF1 and autophagy 134
Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting 134
Circulating tumor cells in breast cancer patients treated by neoadjuvant chemotherapy: A Meta-analysis 134
Gene expression profiling in breast cancer: A clinical perspective 133
A Phase Ib Open-Label Study to Assess the Safety and Tolerability of Everolimus in Combination with Eribulin in Triple-Negative Breast Cancers 132
Could gonadotropin-releasing hormone analogs be helpful in the treatment of triple-negative breast cancer? 131
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for treatment of ovarian cancer 130
null 129
Colorectal cancer-screening program improves both short- and long-term outcomes: a single-center experience in Trieste 129
Risk of hypertension with ramucirumab-based therapy in solid tumors: data from a literature based meta-analysis 129
Is the fatigue an adverse event of the second generation of hormonal therapy? Data from a literature-based meta-analysis 128
New omics information for clinical trial utility in the primary setting 127
Positron emission tomography and neoadjuvant therapy of breast cancer 127
Variations along the 24-hour cycle of circulating osteoprotegerin and soluble RANKL: A rhythmometric analysis 125
Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer 124
Curcumin as an adjunct therapy and microRNA modulator in breast cancer 124
Lower urinary tract infections from external beam radiation therapy in prostate cancer: A single institution experience 124
Erratum to: Advances in systemic therapy for metastatic breast cancer: future perspectives (Medical Oncology, (2017), 34, 7, (119), 10.1007/s12032-017-0975-5) 123
Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines 122
Comparison of molecular subtyping with BluePrint, MammaPrint, and TargetPrint to local clinical subtyping in breast cancer patients 122
Familial aggregation of gastric cancer with microsatellite instability** 122
Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer 122
Biological therapies for metastatic breast cancer: Antiangiogenesis 121
Could the long-term persistence of low serum calcium levels and high serum parathyroid hormone levels during bisphosphonate treatment predispose metastatic breast cancer patients to undergo osteonecrosis of the jaw?[5] 119
International expert consensus on primary systemic therapy in the management of early breast cancer: Highlights of the fourth symposium on primary systemic therapy in the management of operable breast cancer, Cremona, Italy (2010) 119
"Overcoming breast cancer drug resistance with mTOR inhibitors". Could it be a myth or a real possibility in the short-term future? 119
Intermediate endpoints of primary systemic therapy in breast cancer patients 119
Targeting fibroblast growth factor receptor in breast cancer: A promise or a pitfall? 117
Is still there a place for orteronel in management of prostate cancer? Data from a literature based meta-analysis of randomized trials 116
Anti-Angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients 116
Is still there a role for IL-2 for solid tumors other than melanoma or renal cancer? 116
Single Center Experience on Anatomy-and Histopathology-Based Gastric Cancer Molecular Classification 116
Is there a place for bevacizumab in patients with extensive-stage small cell lung cancer? 115
Totale 18.986
Salva come PNG Salva come JPEG
Categoria #
all - tutte 89.563
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 89.563
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204.241 0 0 0 0 0 855 660 534 665 490 618 419
2020/20214.712 468 444 378 532 564 389 440 352 255 349 184 357
2021/20222.804 163 409 197 173 39 197 134 107 380 380 172 453
2022/20233.528 335 361 295 433 368 653 54 313 427 39 178 72
2023/20242.825 120 364 163 188 162 226 476 594 24 122 217 169
2024/20252.663 96 524 834 424 589 196 0 0 0 0 0 0
Totale 31.342